Significance of circulating troponins in heart failure: if these walls could talk.

Biomarkers serve 2 potential roles: They provide insight into the pathophysiology of disease, and they aid clinical decision making by clarifying diagnosis, prognosis, or response to therapy. Fulfillment of one role does not ensure fulfillment of the other. For instance, some biomarkers associated with disease progression turn out to provide little incremental clinical value. Thus, studies like the one by Latini and colleagues1 in this issue of Circulation are valuable because they couple investigation of a biologically interesting association, in this case the link between circulating troponins and heart failure (HF), with a rigorous assessment of clinical utility. The following commentary focuses on 2 questions raised by the study by Latini et al. First, what is the pathophysiological significance of circulating troponins in HF? Second, should we be measuring cardiac troponins in chronic HF patients? Article p 1242 The troponins comprise 3 proteins (troponin T, I, and C) that regulate actin and myosin interactions during muscle contraction. Troponins T and I have distinct isoforms that exist in skeletal and cardiac muscle; newer-generation assays permit the detection of the isoforms unique to cardiac tissue. The release of these proteins into the bloodstream from cardiomyocyte necrosis accounts for their utility as biomarkers of acute coronary syndromes. In the past decade, it has been recognized that elevated concentrations of cardiac troponins also are detectable in patients with HF in the absence of unstable coronary syndromes. In 1997, Missov and colleagues2 used a highly sensitive research assay to demonstrate elevated concentrations of troponin I in 35 patients with advanced HF. Subsequent reports extended these observations to troponin T.3–5 For instance, in a Japanese study, troponin T was detectable by a second-generation assay (detection limit, 0.02 ng/mL) in 30 of 58 patients (52%) with chronic HF compared with 4% of healthy control …

[1]  J. Cohn,et al.  Prognostic Value of Very Low Plasma Concentrations of Troponin T in Patients With Stable Chronic Heart Failure , 2007, Circulation.

[2]  D. Mozaffarian,et al.  The Seattle Heart Failure Model: Prediction of Survival in Heart Failure , 2006, Circulation.

[3]  A. Barbagelata,et al.  Ongoing Myocardial Injury in Stable Severe Heart Failure: Value of Cardiac Troponin T Monitoring for High-Risk Patient Identification , 2004, Circulation.

[4]  D. Levy,et al.  Plasma natriuretic peptide levels and the risk of cardiovascular events and death , 2004 .

[5]  J. Ramires,et al.  Serial measure of cardiac troponin T levels for prediction of clinical events in decompensated heart failure. , 2004, Journal of cardiac failure.

[6]  H. Naruse,et al.  Prognostic value of combination of cardiac troponin T and B-type natriuretic peptide after initiation of treatment in patients with chronic heart failure. , 2003, Clinical chemistry.

[7]  G. Fonarow,et al.  Cardiac Troponin I Is Associated With Impaired Hemodynamics, Progressive Left Ventricular Dysfunction, and Increased Mortality Rates in Advanced Heart Failure , 2003, Circulation.

[8]  T. Takano,et al.  Use of cytosolic and myofibril markers in the detection of ongoing myocardial damage in patients with chronic heart failure. , 2002, The American journal of medicine.

[9]  A. Matsumori,et al.  Serum cardiac troponin T and plasma brain natriuretic peptide in patients with cardiac decompensation , 2002, Heart.

[10]  D. Morrow,et al.  The prognostic value of B-type natriuretic peptide in patients with acute coronary syndromes☆ , 2002 .

[11]  D. Logeart,et al.  Evidence of cardiac myolysis in severe nonischemic heart failure and the potential role of increased wall strain. , 2001, American heart journal.

[12]  K. Kataoka,et al.  Persistently Increased Serum Concentrations of Cardiac Troponin T in Patients With Idiopathic Dilated Cardiomyopathy Are Predictive of Adverse Outcomes , 2001, Circulation.

[13]  M. LeWinter,et al.  Ingenuous interpretation of elevated blood levels of macromolecular markers of myocardial injury: a recipe for confusion. , 2000, Journal of the American College of Cardiology.

[14]  P. Anversa Myocyte death in the pathological heart. , 2000, Circulation research.

[15]  C. di Loreto,et al.  Myocyte death in the failing human heart is gender dependent. , 1999, Circulation research.

[16]  J. Schaper,et al.  The role of cell death in heart failure. , 1999, Circulation research.

[17]  H. Kishida,et al.  Clinical significance of elevated levels of cardiac troponin T in patients with chronic heart failure. , 1999, The American journal of cardiology.

[18]  J. Mair,et al.  A novel biochemical approach to congestive heart failure: cardiac troponin T. , 1999, American heart journal.

[19]  A. Wu,et al.  Release of cardiac troponin in acute coronary syndromes: ischemia or necrosis? , 1999, Clinica chimica acta; international journal of clinical chemistry.

[20]  D. K. Arrell,et al.  Troponin I degradation and covalent complex formation accompanies myocardial ischemia/reperfusion injury. , 1999, Circulation research.

[21]  EmileMissov,et al.  Circulating Cardiac Troponin I in Severe Congestive Heart Failure , 1997 .

[22]  C A Beltrami,et al.  Apoptosis in the failing human heart. , 1997, The New England journal of medicine.

[23]  J. Schwartz,et al.  Development and prospective validation of a clinical index to predict survival in ambulatory patients referred for cardiac transplant evaluation. , 1996, Circulation.

[24]  R. Virmani,et al.  Apoptosis in myocytes in end-stage heart failure. , 1996, The New England journal of medicine.

[25]  P. Poole‐Wilson,et al.  Cellular mechanisms of contractile dysfunction in human heart failure. , 1996, European heart journal.

[26]  E. Sonnenblick,et al.  Stretch-induced programmed myocyte cell death. , 1995, The Journal of clinical investigation.

[27]  E. Sonnenblick,et al.  The cellular basis of dilated cardiomyopathy in humans. , 1995, Journal of molecular and cellular cardiology.

[28]  C A Beltrami,et al.  Structural basis of end-stage failure in ischemic cardiomyopathy in humans. , 1994, Circulation.

[29]  R. Solaro,et al.  Alterations in myofibrillar function and protein profiles after complete global ischemia in rat hearts. , 1992, Circulation research.